ANI Pharmaceuticals (NASDAQ:ANIP) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $77.89 and traded as low as $72.05. ANI Pharmaceuticals shares last traded at $72.61, with a volume of 318,596 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ANIP. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective for the company. Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $99.60.

ANI Pharmaceuticals Stock Down 1.5%

The firm’s 50 day moving average price is $73.33 and its 200-day moving average price is $77.89. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.67 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same period last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the sale, the vice president directly owned 73,424 shares of the company’s stock, valued at approximately $5,403,272.16. This trade represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $71.53, for a total value of $71,530.00. Following the sale, the director directly owned 26,762 shares in the company, valued at approximately $1,914,285.86. The trade was a 3.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 30,412 shares of company stock valued at $2,245,166 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Samalin Investment Counsel LLC boosted its position in shares of ANI Pharmaceuticals by 18.0% in the 3rd quarter. Samalin Investment Counsel LLC now owns 9,283 shares of the specialty pharmaceutical company’s stock worth $674,000 after purchasing an additional 1,418 shares in the last quarter. Kendall Capital Management grew its stake in shares of ANI Pharmaceuticals by 39.9% during the 3rd quarter. Kendall Capital Management now owns 10,345 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 2,950 shares during the period. Sterling Capital Management LLC increased its holdings in ANI Pharmaceuticals by 850.0% during the third quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock valued at $50,000 after buying an additional 612 shares during the last quarter. James Investment Research Inc. raised its holdings in ANI Pharmaceuticals by 4.3% in the 3rd quarter. James Investment Research Inc. now owns 4,850 shares of the specialty pharmaceutical company’s stock worth $352,000 after purchasing an additional 200 shares during the period. Finally, Yousif Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 5.6% during the 3rd quarter. Yousif Capital Management LLC now owns 5,187 shares of the specialty pharmaceutical company’s stock valued at $377,000 after buying an additional 275 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.